Evidence map›Paper›PMID 35631429›Full record

ArticlePharmaceuticals (Basel, Switzerland)2022

Novel Soloxolone Amides as Potent Anti-Glioblastoma Candidates: Design, Synthesis, In Silico Analysis and Biological Activities In Vitro and In Vivo.

Andrey V Markov, Anna A Ilyina, Oksana V Salomatina, Aleksandra V Sen'kova, Alina A Okhina, Artem D Rogachev, Nariman F Salakhutdinov, Marina A Zenkova

Open access · goldAbstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. SoloxoloneInternational journal of molecular sciences · 2025
    Article
  2. Article
  3. SoloxoloneMolecules (Basel, Switzerland) · 2024
    Article
  4. Article
  5. SoloxoloneFrontiers in pharmacology · 2024
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Andrey V MarkovInstitute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia.ORCID 0000-0001-7569-9555
Anna A IlyinaInstitute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia.
Oksana V SalomatinaInstitute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia.
Aleksandra V Sen'kovaInstitute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia.ORCID 0000-0001-5729-9910
Alina A OkhinaFaculty of Natural Sciences, Novosibirsk State University, 630090 Novosibirsk, Russia.
Artem D RogachevFaculty of Natural Sciences, Novosibirsk State University, 630090 Novosibirsk, Russia.ORCID 0000-0002-3338-8529
Nariman F SalakhutdinovN.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia.
Marina A ZenkovaInstitute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia.ORCID 0000-0003-4044-1049
Institute of Chemical Biology and Fundamental Medicine · RUNovosibirsk State University · RUNovosibirsk Institute of Organic Chemistry · RU

Funding

Russian Science Foundation 17-75-20120Russian State funded budget project of ICBFM SB RAS 121031300044-5
6 · The paper itself

Abstract

The modification of natural or semisynthetic triterpenoids with amines can be explored as a promising strategy for improving their pharmacological properties. Here, we report the design and synthesis of 11 novel amide derivatives of soloxolone methyl (

Indexed as

18βH-glycyrrhetinic acidamidesantitumor activityapoptosisbardoxolone methylblood–brain barrierglioblastomamitochondrial stresssoloxolone methyltumor microenvironment

Identifiers

PMID35631429
PMCPMC9145754
OpenAlexW4280637872

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.